Safety and effectiveness of daptomycin across a hospitalized obese population: Results of a multicenter investigation in the southeastern United States

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1322-1330

  Bookstaver, P Brandon ^a   Bland, Christopher M ^b   Qureshi, Zaina P ^a   Faulkner Fennell, Carmen M ^c   Sheldon, Margrit A ^d   Caulder, Celeste R ^a   Hartis, Charles ^e  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b EISENHOWER ARMY MEDICAL CENTER   (United States)

^c Greenville Hospital   (United States)

^d St joseph'S candler Hospital's Candler Emergency Department   (United States)

^e FORSYTH MEDICAL CENTER   (United States)

Author keywords

creatine phosphokinase; daptomycin; HMG Co A reductase; morbid obesity; obesity; Staphylococcus aureus

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ADULT; ARTHRALGIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BODY MASS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; MULTICENTER STUDY (TOPIC); MYALGIA; OBESITY; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

CREATINE PHOSPHOKINASE; DAPTOMYCIN; HMG CO-A REDUCTASE; MORBID OBESITY; OBESITY; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BODY WEIGHT; COHORT STUDIES; CREATINE KINASE; DAPTOMYCIN; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SOUTHEASTERN UNITED STATES; TREATMENT OUTCOME;

EID: 84888027069     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1298     Document Type: Article

References (44)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-7.
2. Nasraway SA Jr, Albert M, Donnelly AM, Ruthazer R, Shikora SA, Saltzman E,. Morbid obesity is an independent determinant of death among surgical critically ill patients. Crit Care Med 2006; 34: 964-70.
3. Herwaldt LA, Cullen JJ, French P, et al. Preoperative risk factors for nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 2004; 25: 481-4.
4. Khawcharoenport T, Tice AD, Grandinetti A, Chow D,. Risk factors for community-associated methicillin-resistant Staphylococcus aureus cellulitis-and the value of recognition. Hawaii Med J 2010; 69: 232-6.
5. Wick EC, Hirose K, Shore AD, et al. Surgical site infections and cost in obese patients undergoing colorectal surgery. Arch Surg 2011; 146: 1068-72.
6. Wisplinhoff H, Bischoff T, Tallent SM, Bischoff T, Wenzel RP, Edmond MB,. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
7. Kilgore M, Brossette S,. Cost of bloodstream infections. Am J Infect Control 2008; 36: S172.e1-3.
8. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U,. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-22.
9. Cheymol G,. Effects of obesity on pharmacokinetics. Clin Pharmacokinet 2000; 39: 215-31.
10. Dossett LA, Dageforde LA, Swenson BR, et al. Obesity and site-specific nosocomial infection risk in the intensive care unit. Surg Infect 2009; 10: 137-42.
11. Forse RA, Karam B, MacLean LD, Christou NV,. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989; 106: 750-7.
12. Freeman JT, Anderson DJ, Hartwig MG, Sexton DJ,. Surgical site infections following bariatric surgery in community hospitals: a weight concern? Obes Surg 2011; 21: 836-40.
13. Cubist Pharmaceuticals. Cubicin (daptomycin for injection) [full prescribing information]. Lexington, MA: Cubist Pharmaceuticals; 2010.
14. Rybak MJ, Hershberger E, Moldovan T, Grucz RG,. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
15. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
16. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
17. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP,. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52: 969-74.
18. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
19. Dvorchik BH, Damphousse D,. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45: 48-56.
20. Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51: 2741-7.
21. Demirovic JA, Pai AB, Pai MP,. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 66: 642-8.
22. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
23. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL,. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: 1568-74.
24. Benvenuto M, Benziger DP, Yankelev S, Vigliani G,. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
25. Figueroa DA, Mangini E, Amodio-Groton M,. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49: 177-80.
26. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC,. Safety and clinical outcomes when utilizing high-dose (≥ 8 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43: 1211-9.
27. Feinglass J, Yarnold PR, McCarthy WJ, Martin GJ,. A classification tree analysis of selection for discretionary treatment. Med Care 1998; 36: 740-7.
28. Yarnold PR,. Discriminating geriatric and nongeriatric patients using functional status information: an example of classification tree analysis via UniODA. Educ Psychol Measur 1996; 56: 656-7.
29. Yarnold PR, Soltysik RC, Bennett CL,. Predicting in-hospital mortality of patients with AIDS-related Pneumocystis carinii pneumonia: an example of hierarchically optimal classification tree analysis. Stat Med 1997; 16: 1451-63.
30. Jacques KA, Erstad BL,. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm 2010; 67: 1948-50.
31. Safdar N, Andes D, Craig WA,. In vivo pharmacodynamics activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-8.
32. Rose WE, Leonard SN, Rybak MJ,. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamics model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 3061-7.
33. Cha R, Grucz RG, Rybak MJ,. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-603.
34. Rybak MJ, McKinnon P, Cha R, et al. Daptomycin pharmacodynamics (PD) versus MRSA at various doses as assessed by a Monte Carlo prediction model. In: Abstracts of the Forty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2008. Abstract 2195. American Society for Microbiology, Washington, DC, USA.
35. Cunha BA, Eisenstein LE, Hamid NS,. Pacemaker-induced Staphylococcus aureus mitral valve acute bacteria endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006; 35: 207-11.
36. Cunha BA, Mickail N, Eisenstein L,. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007; 36: 456-61.
37. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008; 62: 1455-64.
38. Le J, Bookstaver PB, Rudisill CN, et al. Treatment of meningitis causes by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy. Ann Pharmacother 2010; 44: 2001-6.
39. Serrano PE, Khuder SA, Fath JJ,. Obesity as a risk factor for nosocomial infections in trauma patients. J Am Coll Surg 2010; 211: 61-7.
40. Shoker A, Hossain MA, Koru-Sengul T, Raju DL, Cockcroft D,. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 2006; 66: 89-7.
41. Bland CM, Bookstaver PB, Thomas S,. Successful rechallenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin. Int J Antimicrob Agents 2011; 38: 549-50.
42. Odero RO, Cleveland KO, Gelfand MS,. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 2009; 63: 1299-300.
43. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31: 527-36.
44. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.